Evgen Pharma PLC Poster Presentation of SFX-01 and Trial Update (2973J)
December 04 2018 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 2973J
Evgen Pharma PLC
04 December 2018
For immediate release 4 December 2018
Evgen Pharma plc
("Evgen" or "the Company")
Poster presentation of SFX-01 and clinical trial update
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that a trials-in-progress poster of the
Company's Phase II trial of SFX-01 in metastatic breast cancer will
be presented this week at the San Antonio Breast Cancer Symposium
2018 in San Antonio, Texas.
The poster, entitled STEM: SFX-01 in the Treatment and
Evaluation of Metastatic Breast Cancer, will be presented in a
poster session on Wednesday 5 December 2018. The poster gives the
background to SFX-01 along with a description of the STEM trial
including its primary and second endpoints.
After a positive interim readout, recruitment in the STEM trial
concluded in July this year. The final patient on the trial will
take her last dose of SFX-01 before the end of December 2018,
meaning that the final readout of the trial is expected in February
or March 2019.
The San Antonio Breast Cancer Symposium is on 4-8 December 2018
in San Antonio, Texas, at the Henry B. Gonzalez Convention Center.
Further information is available at this link: www.sabcs.org.
A copy of the Evgen poster will be made available on the
Company's website, www.evgen.com, following its presentation at the
San Antonio symposium.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Tilly Abraham +44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney (Corporate
Finance)
Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage, a
type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office at the Liverpool Science Park, Liverpool. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDFSLFWDFASEDE
(END) Dow Jones Newswires
December 04, 2018 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024